Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138578 · ClinicalTrials.gov registry record · NA
Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma
A NA study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02138578 is a NA study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 4 participants.
The verdict
NCT02138578, a NA study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will assess whether Stereotactic Body Radiation Therapy (SBRT) can provide comparable local control, with similar or improved toxicity rates compared to Radio Frequency Ablation (RFA) when treating small renal cell carcinomas.
Interventions
- RADIATION SBRT
- RADIATION RFA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02138578
The ClinicalTrials.gov registry entry for NCT02138578 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SBRT is the first listed.
NCT02138578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02138578 about?
NCT02138578 is a clinical study titled "Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma". This study will assess whether Stereotactic Body Radiation Therapy (SBRT) can provide comparable local control, with similar or improved toxicity rates compared to Radio Frequency Ablation (RFA) when treating small renal cell carcinomas.
What is the current status of trial NCT02138578?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2014-05. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02138578?
The interventions under investigation include: SBRT (RADIATION), RFA (RADIATION).
Who is sponsoring clinical trial NCT02138578?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.